TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT
https://doi.org/10.21518/2079-701X-2017-6-51-55
Abstract
The advances in molecular biology have had a considerable influence on the medicinal treatment of patients with small cell lung cancer (NSCLC). The discovery of targets and development of drugs for molecular-targeted action improved the results of therapy of a specific group of patients. Translocation (rearrangeable) gene ROS-1 is quite rare – only in 1.7 percent of NSCLC patients. In addition to the genetic characteristics of the tumor, there are a number of morphological features that differentiate these patients from the general population. The most important is the fact that ROS-1 positive patients were very sensitive to crizotinib-tyrosine kinase inhibitor of ALK, MET and ROS1. Immediate effectiveness and long-term results of the use of crizotinib in this category of patients was even higher than the ALK translocation in the tumor. Therefore, it is advisable for patients, particularly with adenocarcinoma of the lung, in the absence of EGFR mutation and ALK to conduct molecular-genetic testing to determine ROS1. Individual approach to the choice of treatment strategy, timely correction of undesirable effects can greatly extend the life of NSCLC patients and improve its quality.
About the Authors
K. K. LAKTIONOV
Blokhin Russian Oncologic Scientific Center of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
E. V. REUTOVA
Blokhin Russian Oncologic Scientific Center of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
M. S. ARDZINBA
Blokhin Russian Oncologic Scientific Center of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
N. A. MESCHERYAKOVA
Blokhin Russian Oncologic Scientific Center of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Johnson BE, et al. 2013 ASCO Abstract 8019.
2. Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer, 2003, 37: 58-71.
3. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 2007, 131: 1190-1203.
4. Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One, 2011, 6(1): e15640.
5. Lee J, Lee SE, Kang SY, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer, 2013, 119: 1627-1635.
6. Birch AH, Arcand SL, Oros KK, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One, 2011, 6(12): e28250.
7. SH Ou, Jackie Tan , Yun Yen et al. ROS1 as a ‘Druggable’ Receptor Tyrosine Kinase: Lessons Learned From Inhibiting the ALK Pathway. Expert Rev Anticancer Ther, 2012, 12(4): 447-456.
8. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med, 2012, 18: 378-381,
9. Bergethon K1, Shaw AT, Ou SH ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012 Mar 10, 30(8): 863-70.
10. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion patternspecific clinicopathologic, histologic and cytologic features. Lung Cancer, 2014, 84: 121-126.
11. Warth A, Muley T, Dienemann H, et al. ROS1 expression and translocations in non-small- cell lung cancer: Clinicopathological analysis of 1478 cases. Histopathology, 2014, 65: 187- 194.
12. Yen-Fu Chen, Min-Shu Hsieh, Shang-Gin Wu et al. Сlinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations. J Thorac Oncol, 2014, 9: 1171-1179.
13. Yasuda H1, de Figueiredo-Pontes LL, Kobayashi S et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1- translocated lung cancer. J Thorac Oncol, 2012 Jul, 7(7): 1086-90.
14. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med, 2010, 363: 1693-1703.
15. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014 Nov 20, 371(21): 1963-71.
16. Mazières J, Zalcman G, Crinò L et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol, 2015 Mar 20, 33(9): 992-9.
17. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 2012, 13: 1011-1019.
18. Huber KV, Salah E, Radic B, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 2014, 508: 222-227.
19. Yoshida A, Kohno T, Tsuta K et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol, 2013, 37: 554-562.
20. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74–ROS1. N Engl J Med, 2013, 368: 2395-2401.
21. Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One, 2013, 8(12): e82236.
22. Gettinger SN, Bazhenova L, Salgia R, et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). Presented at the Annual Meeting of the American Society of Clinical Oncology, May 30–June 3, 2014, Chicago. abstract.
23. Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5- chloro-N2-(2-isopropoxy- 5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine(LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem, 2013, 56: 5675-5690.
24. Katayama R, Kobayashi Y, Friboulet L. Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer. Clin Cancer Res, 2015 Jan 1, 21(1): 166-174.
25. Facchinetti F, Loriot Y, Kuo M-Sh, et al. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Clin Cancer Res, 2016, December 15, 22(24): 5983-5991. DOI: 10.1158/1078-0432.CCR-16-0917. Published 17 November 2016.
Review
For citations:
LAKTIONOV KK, REUTOVA EV, ARDZINBA MS, MESCHERYAKOVA NA. TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT. Meditsinskiy sovet = Medical Council. 2017;(6):51-55. (In Russ.) https://doi.org/10.21518/2079-701X-2017-6-51-55
Views:
904
Email this article 